Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Almirall ( (ES:ALM) ) has shared an announcement.
Almirall has announced the divestment of its product Algidol® and the licensing of Sekisan® in Spain, receiving €12 million upfront and additional future payments. This move is part of Almirall’s strategy for portfolio rotation and management, potentially streamlining its focus and enhancing financial flexibility.
More about Almirall
Almirall is a pharmaceutical company focusing on the development and marketing of medical products. The company specializes in dermatology and other therapeutic areas, providing treatments for a variety of health conditions.
YTD Price Performance: 17.08%
Average Trading Volume: 3,882
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €2.03B
See more insights into ALM stock on TipRanks’ Stock Analysis page.